Soraires Santacruz María C, Fabiani Matías, Castro Eliana F, Cavallaro Lucía V, Finkielsztein Liliana M
Cátedra de Química Medicinal, Departamento de Farmacología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, 1113 Ciudad Autónoma de Buenos Aires, Argentina; Instituto de Química y Metabolismo del Fármaco (IQUIMEFA), Consejo Nacional de Investigaciones Científicas y Técnicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, 1113 Ciudad Autónoma de Buenos Aires, Argentina.
Cátedra de Virología, Departamento de Microbiología, Inmunología y Biotecnología, Consejo Nacional de Investigaciones Científicas y Técnicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, 1113 Ciudad Autónoma de Buenos Aires, Argentina.
Bioorg Med Chem. 2017 Aug 1;25(15):4055-4063. doi: 10.1016/j.bmc.2017.05.056. Epub 2017 May 27.
A series of N-arylsubstituted thiosemicarbazones derived from 1-indanones and a set of compounds lacking such substitution in the N position of the thiosemicarbazone moiety were synthesized and evaluated for their anti-bovine viral diarrhea virus (BVDV) activity. Among these, derivatives 2 and 15 displayed high activity (EC=2.7±0.4 and 0.7±0.1µM, respectively) as inhibitors of BVDV replication. Novel key structural features related to the anti-BVDV activity were identified by structure-activity relationship (SAR) analysis. In a previous study, the thiosemicarbazone of 5,6-dimethoxy-1-indanone (5,6-TSC) was characterized as a non-nucleoside inhibitor (NNI) of the BVDV RNA-dependent RNA polymerase. In the present work, cross-resistance assays were performed with the most active compounds. Such studies were carried out on 5,6-TSC resistant BVDV (BVDV-TSC T1) carrying mutations in the viral polymerase. This BVDV mutant was also resistant to compound 15. Molecular docking studies and MM/PBSA calculations were performed to assess the most active derivatives at the 5,6-TSC viral polymerase binding site. The differences in the interaction pattern and the binding affinity of derivative 15 either to the wild type or BVDV-TSC T1 polymerase were key factors to define the mode of action of this compound.
合成了一系列由1-茚酮衍生的N-芳基取代硫代氨基脲以及一组在硫代氨基脲部分的N位缺乏此类取代的化合物,并对其抗牛病毒性腹泻病毒(BVDV)活性进行了评估。其中,衍生物2和15作为BVDV复制抑制剂表现出高活性(EC分别为2.7±0.4和0.7±0.1μM)。通过构效关系(SAR)分析确定了与抗BVDV活性相关的新关键结构特征。在先前的研究中,5,6-二甲氧基-1-茚酮的硫代氨基脲(5,6-TSC)被表征为BVDV RNA依赖性RNA聚合酶的非核苷抑制剂(NNI)。在本研究中,对活性最高的化合物进行了交叉耐药性试验。此类研究是在病毒聚合酶中携带突变的5,6-TSC耐药BVDV(BVDV-TSC T1)上进行的。该BVDV突变体对化合物15也具有抗性。进行了分子对接研究和MM/PBSA计算,以评估5,6-TSC病毒聚合酶结合位点处活性最高的衍生物。衍生物15与野生型或BVDV-TSC T1聚合酶相互作用模式和结合亲和力的差异是确定该化合物作用模式的关键因素。